Rexulti lowers dementia-related neuropsychiatric and agitation symptoms in late-stage trial
Otsuka said that Rexulti (brexpiprazole) has demonstrated its efficacy in two Phase 3 trials involving patients with agitation related to dementia due to Alzheimer’s disease. The company’s US-based